Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Silo Pharma Inc (NQ: SILO )

1.900 -0.070 (-3.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 32,095
Open 1.990
Bid (Size) 1.870 (1)
Ask (Size) 1.980 (5)
Prev. Close 1.970
Today's Range 1.900 - 2.020
52wk Range 1.216 - 3.050
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Plans for Exclusive Licensing of Novel Therapeutic for Alzheimer’s Disease
Via Investor Brand Network

Performance

YTD
+25.00%
+25.00%
1 Month
+6.15%
+6.15%
3 Month
+31.72%
+31.72%
6 Month
+35.71%
+35.71%
1 Year
-15.93%
-15.93%

More News

Read More
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic
From Silo Pharma, Inc.
Via GlobeNewswire
Citizens And 2 Other Stocks Under $3 Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
Via Benzinga
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Via Benzinga
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
Via Benzinga
Topics Economy
Exposures Interest Rates
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Exercises Option for Exclusive License Agreement for SPC-15
Via Investor Brand Network
Exposures Product Safety
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Patent Application for Groundbreaking Ketamine Implant Therapeutic
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
From Silo Pharma, Inc.
Via GlobeNewswire
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Completes Successful Dose-Ranging Study in Advancement of SPC-15
Via Investor Brand Network
Exposures Product Safety
Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
From Silo Pharma, Inc.
Via GlobeNewswire
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
Via Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Validation of Delivery System for SP-26
Via Investor Brand Network
Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Prioritize Clinical Pipeline Targeting Mental Health, Chronic Pain and Neurology
Via Investor Brand Network
Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
From Silo Pharma, Inc.
Via GlobeNewswire
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Highlights Positive Results of Alzheimer’s Study
Via Investor Brand Network
Silo Pharma Announces Positive Results in Alzheimer’s Disease Study
From Silo Pharma, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.